Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy

NCT07721025 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Friedreich Ataxia
Cardiomyopathy, Secondary

Interventions

GENETIC: LX2006
OTHER: Usual Care

Sponsor

Lexeo Therapeutics